Browse by Audience
Skip to content
Papers of the Week
Adverse events associated with Atogepant: a faers-based pharmacovigilance analysis.
Authors
Zhang Y, Sun S, Wang YAbstract
Migraine,a prevalent neurovascular disorder,can significantly disrupt an individual’s daily life.Atogepant (AGN-241689),an orally administered small molecule drug classified as a calcitonin gene-related peptide receptor antagonist,is utilized for prophylactic migraine treatment.The objective of this study was to investigate adverse events (AEs) associated with atogepant through data mining in the FDA Adverse Event Reporting System (FAERS) to enhance clinical safety.